Market closed
Amylyx Pharmaceuticals, Inc./$AMLX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.
Ticker
$AMLX
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
123
Website
AMLX Metrics
BasicAdvanced
$353M
-
-$4.43
-0.51
-
Price and volume
Market cap
$353M
Beta
-0.51
52-week high
$4.12
52-week low
$2.60
Average daily volume
798K
Financial strength
Current ratio
6.669
Quick ratio
6.233
Long term debt to equity
0.281
Total debt to equity
1.202
Management effectiveness
Return on assets (TTM)
-51.31%
Return on equity (TTM)
-100.88%
Valuation
Price to revenue (TTM)
3.104
Price to book
1.66
Price to tangible book (TTM)
1.66
Price to free cash flow (TTM)
-1.329
Growth
Revenue change (TTM)
-77.06%
Earnings per share change (TTM)
-732.86%
3-year revenue growth (CAGR)
574.28%
3-year earnings per share growth (CAGR)
-30.77%
AMLX News
AllArticlesVideos
Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm
GlobeNewsWire·3 days ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Stockholders to Connect
Accesswire·4 days ago
Amylyx Pharmaceuticals, Inc. (AMLX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Accesswire·6 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Amylyx Pharmaceuticals, Inc. stock?
Amylyx Pharmaceuticals, Inc. (AMLX) has a market cap of $353M as of April 19, 2025.
What is the P/E ratio for Amylyx Pharmaceuticals, Inc. stock?
The price to earnings (P/E) ratio for Amylyx Pharmaceuticals, Inc. (AMLX) stock is 0 as of April 19, 2025.
Does Amylyx Pharmaceuticals, Inc. stock pay dividends?
No, Amylyx Pharmaceuticals, Inc. (AMLX) stock does not pay dividends to its shareholders as of April 19, 2025.
When is the next Amylyx Pharmaceuticals, Inc. dividend payment date?
Amylyx Pharmaceuticals, Inc. (AMLX) stock does not pay dividends to its shareholders.
What is the beta indicator for Amylyx Pharmaceuticals, Inc.?
Amylyx Pharmaceuticals, Inc. (AMLX) has a beta rating of -0.51. This means that it has an inverse relation to market volatility.